| P – Patients undergoing induction treatment for AML |
| I – Use of cytarabine (400 mg/m2/day, 1 g/m2, 1.5 g/m2 or 3 g/m2) |
| C – |
| O – Complete remission rate, overall survival, and disease-free survival |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.